A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Details
Age
Adult
Type of Study
Treatment
Locations
Highlands Ranch Hospital
University of Colorado Hospital
Principal Investigator
Elaine Lam, MD
Study ID
Protocol Number: 23-1122
More information available at ClinicalTrials.gov: NCT05678673
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers